Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work.  The vision is of a common clinical-trial […] Continue reading ->
China’s financial hub Shanghai continues to see rising COVID-19 cases despite the country’s attempts at a “no COVID” policy.  The city reported over 27,000 coronavirus cases on Thursday, a new high, following Chinese President Xi Jinping’s announcement a day earlier reinforcing the zero-tolerance approach to COVID.  “Prevention and control work cannot be relaxed,” Xi said […] Continue reading ->
Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control.  “I’m stunned that the proposed IP waiver is still being debated while supplies […] Continue reading ->
Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading ->
In a highly symbolic visit to Lviv, Ukraine, World Health Organization Regional Director Hans Kluge reaffirmed WHO’s commitment to rebuilding the country’s war-torn health system.   Speaking in a press briefing staged directly from Lviv, Kluge said, “We are committed to work through a decentralized footprint [in Ukraine], both during the current humanitarian response but also […] Continue reading ->